

Curriculum Vitae for: GIL LICHTSHEIN, M.D.

**Gil Lichtshein, M.D., P.A.
7200 West Camino Real, Suite 220
Boca Raton, FL 33433**

**University of Miami Life Science and Technology Park
1951 NW 7th Ave, Suite 300
Miami, FL 33136**

Tel: 561-300-4052

Email: info@docgil.com

Web: www.docgil.com and www.southfloridatms.com

EDUCATION

Child and Adolescent Psychiatry Fellowship University of Maryland at Baltimore
Baltimore, MD 21201
July 1997-June 1999
(Including Child Psychiatry Chief Fellow January 1999-June 1999)

PGY-2, PGY-3, Psychiatry University of Maryland at Baltimore
Baltimore, MD 21201
July 1995-June 1997

PGY-1, Psychiatry Medical College of Virginia Hospital
Virginia Commonwealth University
Richmond, VA 23298
June 1994-June 1995
(Including 3 months Pediatrics, 2 months Neurology, 1 month Emergency Medicine)

M.D., University of Illinois at Chicago College of Medicine
Chicago, IL 60612
August 1990-May 1994

B.A. Yeshiva University
New York, NY 10033
August 1988-May 1990
Major: History

Loyola University of Chicago
Chicago, IL 60626
August 1986-May 1988

HONORS

Undergraduate Dean's List: 1986-1990

Summa Cum Laude, Yeshiva University, May 1990

Child Psychiatry Chief Fellow, University of Maryland at Baltimore, January-June 1999

CERTIFICATIONS

American Board of Psychiatry and Neurology, Inc., Psychiatry, Certificate # 48062

American Board of Psychiatry and Neurology, Inc., Child and Adolescent Psychiatry
Certificate # 5061

ACADEMIC APPOINTMENTS

Courtesy Assistant Professor of Psychiatry, University of Florida School of Medicine
Department of Psychiatry, Gainesville, FL, 12/12/08-present

Voluntary Assistant Professor of Psychiatry and Behavioral Sciences, University of
Miami Miller School of Medicine Department of Psychiatry, Miami, FL, 11/13/08-
present

Affiliate Clinical Assistant Professor of Clinical Biomedical Sciences, Charles E.
Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 1/21/05-
Present

Assistant Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of
Medicine, Bronx, NY, 2000-2004

LICENSURE

Licensed to practice medicine in the state of Florida, #ME87712

PUBLICATIONS

Fernandez A. **Lichtsheim G.** (1995) THE Charles Bonnet Syndrome. Correspondence.
British Journal of Psychiatry. 167, 115.

Fernandez A. **Lichtsheim G.** Viewer W. V.R. and Winfrey C. J. (1996) Charles Bonnet
Syndrome with Peripheral and Central Findings-a Case Report.
International Journal of Geriatric Psychiatry, 11-773-778.

Fernandez A. **Lichtsheim G.** and Viewer W.V.R, (1997) The Charles Bonnet Syndrome:
A review. *The Journal of Nervous and Mental Disease,* 185: 195-200.

CLINICAL RESEARCH

- 2011- Present Sub-Investigator, Health Sciences America, Inc, Boca Raton, FL
- Sub-Investigator, Merck. 26 Week Open Label Flexible Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I D/O, 2011
- Sub-Investigator, Merck. Efficacy and Safety of 3 Week Fixed Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episode Associated with Bipolar I D/O, 2011
- 2005– Present Clinical Investigator, Psychopharmacology Research, Florida Atlantic University, Dept of Integrated Medical Science, Charles E. Schmidt College of Medicine, Boca Raton, FL.
- Clinical Investigator, Eli Lilly and Company. A phase 3 randomized, double-blind, placebo controlled study of the safety and effectiveness of immune globulin intravenous, 10% solution for the treatment of mild to moderate Alzheimer’s Disease, 2013.
- Clinical Investigator, Eli Lilly and Company. Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab versus Placebo, 2013.
- Clinical Investigator, Eisai Medical Research Inc. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease, 2013
- Clinical Investigator, Genetech/Roche. A Multicenter, Open-Label, Long-term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer’s Disease, 2013
- Clinical Investigator, Baxter. A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of

Immune Globulin Intravenous(Human), 10% Solution(IGIV, 10%)
for the Treatment of Mild to Moderate Alzheimer's Disease, 2012

Clinical Investigator, Takeda. A Randomized Double-Blind,
Parallel-Group, Active-Controlled, Flexible-Dose Study
Evaluating the Effect of Lu AA21004 v Escitalopram on Sexual
Functioning in Adults With Well-Treated Major Depressive
Disorder Experiencing Selective Serotonin Reuptake Inhibition-
Induced Sexual Dysfunction, 2011

Clinical Investigator, Genentech. A Radomized Double Blind,
Placebo Controlled , Parallel Group, Multicenter, Phase II Study
To Evaluate The Efficacy And Safety Of MABT5102A In Patients
With Mild To Moderate Alzheimer's Disease, 2011

Clinical Investigator, Eli Lilly and Compnay. Contiued Efficacy
and Safety Monitoring of Solanezumab, an Anti-Amyloid Beta
Antibody in Patients with Alzheimer's Disease, 2011

Clinical Investigator, Novartis. A 24 week Open-Label Extension
to a 24 Week Prospective, Randomized, Parallel-Group, Double-
Blind, Multi Center Study Comparing the Effects of Rivastigmine
Patch 15cm² Vs. Rivastigmine Patch 5 cm² on Activities of Daily
Living and Cognition in Patients with Severe Dementia of the
Alzheimer's Type, 2010

Clinical Investigator, Forest Research Institute. A Double-blind,
Placebo-Controlled Flexible-Dose Study of F2695 SR in Patients
With Major Depressive Disorder, 2009

Clinical Investigator, Novartis. A 24 week Prospective,
Randomized, Parallel-Group, Double-Blind, Multi Center
Study Comparing the Effects of Rivastigmine Patch 15cm²
Vs. Rivastigmine Patch 5 cm² on Activities of Daily Living and
Cognition in Patients with Severe Dementia of the Alzheimer's
Type, 2009

Clinical Investigator. Pfizer. A Phase 3, Randomized, Double-
Blind, Parallel Group, 10-week Placebo Controlled Fixed Dose
Study of PD 0332334 for the Treatment of Generalized Anxiety
Disorder, 2008

Clinical Investigator. Pfizer. A 52 Week Open-Label Safety Study
of PD 0332334 in Subjects with Generalized Anxiety Disorder,
2008

Sub Investigator for Schwarz-Pharma trial, A Multicenter Randomized, Open Label Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment with Nirivam and an SSRI or SNRI to Treatment with an SSRI or SNRI Alone in Subjects with Generalized Anxiety Disorder or Panic Disorder, 2007

PRESENTATIONS

Lichtsheim G. and Fernandez A. “Organic hallucinosis in the visually impaired”, Presented at the Department of Ophthalmology Grand Rounds, MCV Hospital, Richmond, VA February 1995.

Lichtsheim G, Fernandez A. and Dixon L.B. A central hypothesis for the Charles Bonnet Syndrome presented at the American Psychiatric Association 149th Annual Meeting, New York, NY, Young Investigator’s Poster Session, May 6, 1996.

“Child and Adolescent Depression”, Mt. St. Mary’s College, Newburgh, NY May 23, 2001

“Update on medications and ADHD and co morbid disorders; including the many new extended release formulations”, CHADD of Putnam and Vicinity, Katonah, NY December 3, 2002

“Management of Childhood OCD”, La Viella Maison, Boca Raton, FL, October 29, 2003

“Medication 101”, The Coalition Group, Boca Raton, FL November 20, 2003

“Medication 101”, The Coalition Group, Boca Raton, FL February 13, 2003

“ADHD: Update on Treatment” CHADD of North Broward, Coral Springs, FL February 24, 2004

“Pharmacological Treatment of Asperger’s”, Center for Autism and Related Disabilities, Boca Raton, FL September 21, 2004

Pharmacological Treatment of Asperger’s”, Center for Autism and Related Disabilities, Jupiter, FL October 26, 2004

“Basic Principals of Psychopharmacology”, Dan Marino Center, Weston, FL December 12, 2004

OCD v Healthy Ritual Observance, South Florida Orthodox Mental Health Retreat.
Sunny Isles Beach, FL March 11, 2005

Intensive Skills Training: What Are We Dealing With Here? Psycho diagnostic
Assessment Strategies for Challenging Diagnostic Cases, South Florida Orthodox Mental
Health Retreat. Sunny Isles Beach, FL March 13, 2005

Mental Status Exam, Presentation to First year Medical Students, Charles E Schmidt
College of Medicine, January 24, 2013

Pediatric Autism Spectrum Disorder: An Overview, University Learning Systems,
Eastern Caribbean Cruise, March 15, 2013

EMPLOYMENT

South Florida TMS, LLC
Boca Raton and Miami, FL
Medical Director
July 2015-

Chrysalis TMS Institute, Inc
Boca Raton and Miami, FL
Medical Director
June 2013-July 2015

Gil Lichtshein, M.D., P.A.
7100 West Camino Real, Suite 302
Boca Raton, FL 33433
Psychiatrist/President
January 2009- present

Health Sciences America, Inc.
1515 N. Federal Hwy; Suite 215
Boca Raton, FL 33432
Sub-Investigator
Jan 2006 – July 2015

Boca Raton Psychiatric Group
7284 W. Palmetto Park Road, Suite 201
Boca Raton, FL 33433
Psychiatrist/Partner
August 2003-December 2008

Four Winds Hospital
Katonah, NY 10536
Medical Director, Cliffside Children's Inpatient Unit
Medical Director, Child and Adolescent Partial Hospitalization Program
October 2000-August 2003

Private Practice
Katonah, NY 10536
February 2001-August 2003

St Christopher Otilie, Inc.
Bronx Family Based Treatment Program
Bronx, NY 10461
Psychiatric Consultant
August 1999-May 2001

Bronx Lebanon Hospital Center
Department of Psychiatry
Bronx, NY 10457
Staff Psychiatrist
July 1999-October 2000

PROFESSIONAL ORGANIZATIONS

Fellow, American Psychiatric Association
Fellow, American Academy of Child and Adolescent Psychiatry
South Florida Regional Council
Member, Fifteenth Judicial Circuit Grievance Committee "C", 4/07-3/10

PERSONAL

HOBBIES: Reading, Sports, Civil War History, Travel, Exotic Foods